Cartesian Therapeutics Inc.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that provides mRNA cell therapies for treating autoimmune diseases. Its lead product candidate, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell (CAR-T) therapy targeting the B cell maturation antigen (BCMA). Descartes-08 is in Phase 2b clinical trials for autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, and has rare pediatric disease designation for juvenile dermatomyositis. The company is also developing Descartes-15, an autologous BCMA-directed mRNA CAR-T in Phase 1 trials for patients with multiple myeloma. Cartesian Therapeutics is headquartered in Frederick, Maryland.

RNAC▼

Zacks Adds Caesars Entertainment, Cartesian Therapeutics, and Insperity to Strong Sell List

Zacks Investment Research added three stocks to its Zacks Rank #5 (Strong Sell) List today. Caesars Entertainment saw its current-year earnings consensus estimate revised 104.2% downward over the last 60 days. Cartesian Therapeutics had its estimate cut by 7%, while Insperity's estimate was revised 11.6% lower over the same period.

CZR ▼NSP ▼RNAC ▼

CZR · Capital · Negative Earnings consensus estimate revised 104.2% downward over 60 days

NSP · Capital · Negative Earnings consensus estimate revised 11.6% lower over 60 days

RNAC · Capital · Negative Earnings consensus estimate cut by 7% over 60 days

Read original ↗

Zacks Investment Research·95dRead more →